Results of CRT in Large Randomized, Clinical Trials
| Trial | Design | No. of patients | Summary of results |
|---|---|---|---|
| MIRACLE (2) | Parallel arms | 453 | Improvement in NYHA functional class, QoL, 6MWT, LVEF, LVEDD, and MR |
| CONTAK-CD (3) | Crossover, parallel controlled | 490 | Improvement in NYHA functional class, QoL, 6MWT, LVEF, and LV volumes |
| MUSTIC-SR (4) | Crossover | 58 | Improvement in NYHA functional class, QoL, 6MWT, LV volumes, MR, and peak Vo2; reduction in hospitalizations |
| PATH-CHF (5) | Crossover | 41 | Improvement in NYHA functional class, QoL, and 6MWT; reduction in hospitalizations |
| PATH-CHF II (6) | Crossover (no pacing vs. LV pacing) | 86 | Improvement in QoL, 6MWT, and peak Vo2 |
| MIRACLE-ICD (7) | Parallel arms | 555 | Improvement in NYHA functional class and QoL |
| COMPANION (8) | Parallel arms | 1,520 | Reduction in all-cause mortality and hospitalizations |
| CARE-HF (9) | Open-label, randomized | 814 | Reduction in mortality and hospitalizations; improvement in NYHA functional class, QoL, LVEF, and LVESV |
MIRACLE = Multicenter Insync Randomized Clinical Evaluation; NYHA = New York Heart Association; QoL = quality of life score; 6MWT = 6-min walk test; LVEF = left ventricular ejection fraction; LVEDD = left ventricular end-diastolic diameter; MR = mitral regurgitation; CONTAK-CD = CONTAK-Cardiac Defibrillator; MUSTIC-SR = Multisite Stimulation in Cardiomyopathies-Sinus Rhythm; PATH-CHF = Pacing Therapies in Congestive Heart Failure; PATH-CHF II = Pacing Therapies in Congestive Heart Failure-II; MIRACLE-ICD = Multicenter Insync Randomized Clinical Evaluation-Implantable Cardioverter Defibrillator; COMPANION = Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure; CARE-HF = Cardiac Resynchronization-Heart Failure; Vo2 = volume of oxygen; LVESV = left ventricular end-systolic volume.